TELA Bio, Inc. files 10-Q

TELA Bio, Inc. reported a net loss of $12.3 million for the first quarter of 2026, an increase from the $11.3 million net loss in the same period of 2025. Revenue grew slightly to $19.1 million, driven by international sales, but gross margin decreased due to higher inventory costs. The company believes its current cash of $39.5 million is sufficient for at least the next 12 months, supported by a $60 million credit facility.